BIOCRYST PHARMACEUTICALS INC updated its the quarter ended March 31, 2026 guidance (reaffirmed).
“BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a business update.”
BIOCRYST PHARMACEUTICALS INC — fact timeline
Source-grounded facts extracted from BIOCRYST PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIOCRYST PHARMACEUTICALS INC entered into Loan Agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., as Blackstone representatives, the lenders party thereto, and Wilmington Trust, National Association, as agent valued at $400 million (effective 2026-01-23).
“On January 23, 2026 (the “ Closing Date ”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ”), entered into a Loan Agreement (the “ Loan Agreement ”), by and among BioCryst, as borrower, the guarantors from time to time party thereto, Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., as the Blackstone representatives thereunder, the lenders from time to time party thereto and Wilmington Trust, National Association, as agent. The Loan Agreement provides for initial term loans in the principal amount of $400 million (the “ Term Loans ”), which were funded on the Closing Date.”
George B. Abercrombie retired as Director at BIOCRYST PHARMACEUTICALS INC.
“On June 11, 2025, George B. Abercrombie notified BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), of his intention to retire from the Board of Directors of the Company (the “Board”), effective as of the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).”
Steven Frank was elected as Director at BIOCRYST PHARMACEUTICALS INC.
“On April 30, 2025, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) approved an increase in the size of the Board from ten to eleven directors and elected Steven Frank to fill the vacancy created by the enlargement of the Board, effective May 2, 2025 (the “Effective Date”).”
Jon P. Stonehouse was appointed as Interim Chief Financial Officer and Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.
“appointed Jon P. Stonehouse, the Company’s Chief Executive Officer, to serve as Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of the Effective Date.”
Anthony Doyle resigned as Chief Financial Officer and Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.
“Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025”
Anthony Doyle resigned as Chief Financial Officer at BIOCRYST PHARMACEUTICALS INC.
“On February 28, 2025, Anthony Doyle, the Chief Financial Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025.”
BIOCRYST PHARMACEUTICALS INC reported the first quarter ended March 31, 2024 results: revenue $92.8 million, net income $35.4 million, EPS $0.17 per share. Guidance raised.
“said Dr. Helen Thackray, chief research and development officer of BioCryst. First Quarter 2024 Financial Results For the three months ended March 31, 2024, total revenues were $92.8 million, compared to $68.8 million in the first quarter of 2023 (+34.9 percent y-o-y). The increase was primarily due to $88.9 million in ORLADEYO net revenue in the first quarter of”
BIOCRYST PHARMACEUTICALS INC updated its the fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).
“On February 26, 2024, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the fourth quarter and full year ended December 31, 2023, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.”
BIOCRYST PHARMACEUTICALS INC: Amended and Restated By-Laws effective January 16, 2024, including updates to align with Delaware law, revisions to stockholder meeting and nomination procedures, universal proxy rules, and technical changes (effective 2024-01-16).
“On January 16, 2024, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company” or “BioCryst”) approved and adopted Amended and Restated By-Laws of the Company (as so amended and restated, the “By-Laws”), that became effective immediately.”
BIOCRYST PHARMACEUTICALS INC reported full year 2024 results: revenue 380-400. Guidance reaffirmed.
“Guidance and Accelerated Path to Profitability —ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales— —Operating expenses expected to remain flat ($365-$375 million) in 2024— —Company expects operating profit in”
Kenneth B. Lee, Jr. departed as Director at BIOCRYST PHARMACEUTICALS INC.
“On November 28, 2023, Kenneth B. Lee, Jr. notified BioCryst Pharmaceuticals, Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”), effective December 31, 2023.”
BIOCRYST PHARMACEUTICALS INC reported the third quarter ended September 30, 2023 results: revenue $86.7 million, net income $36.1 million, or $0.19 per share. Guidance reaffirmed.
“in the investors section of the company website at www.biocryst.com. Third Quarter 2023 Financial Results For the three months ended September 30, 2023, total revenues were $86.7 million, compared to $75.8 million in the third quarter of 2022 (+14.4 percent y-o-y). The increase was primarily due to an increase in ORLADEYO net revenue of $19.7 million, partially”
BIOCRYST PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $82.5 million, net income Net loss for the second quarter of 2023 was $75.3 million, or $0.40 per share, EPS $0.40 per share. Guidance raised.
“For the three months ended June 30, 2023, total revenues were $82.5 million, compared to $65.5 million in the second quarter of 2022 (+25.9 percent year-over-year (y-o-y)).”
Anthony Doyle was appointed as Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.
“On July 10, 2023, the Board of Directors of the Company appointed Anthony Doyle, the Company’s Chief Financial Officer, to serve as interim Principal Accounting Officer, effective as of the same date.”
Michael L. Jones resigned as Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.
“On July 7, 2023, Michael L. Jones, Executive Director, Finance and Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”), informed the Company of his intention to resign from the Company.”
BIOCRYST PHARMACEUTICALS INC updated its full year 2023 guidance (reaffirmed).
“The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million.”
BIOCRYST PHARMACEUTICALS INC reported first quarter ended March 31, 2023 results: revenue $68.8 million, net income Net loss of $53.3 million, or $0.28 per share, EPS $0.28 per share. Guidance reaffirmed.
“For the three months ended March 31, 2023, total revenues were $68.8 million”
BIOCRYST PHARMACEUTICALS INC incurred credit facility of $450 million Loan Agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership at three-month SOFR rate, which shall be no less than 1.75% (“SOFR”), plus 7.00%, p maturing April 17, 2028.
“On April 17, 2023, BioCryst Pharmaceuticals, Inc. (the “Company”) entered into a $450 million Loan Agreement by and among the Company, as borrower; the guarantors from time to time party thereto; BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders thereunder; and BioPharma Credit PLC, as collateral agent for the lenders (the “Credit Agreement”).”
BIOCRYST PHARMACEUTICALS INC entered into Credit Agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders; BioPharma Credit PLC, as collateral agent valued at $450 million (effective 2023-04-17).
“On April 17, 2023, BioCryst Pharmaceuticals, Inc. (the “Company”) entered into a $450 million Loan Agreement by and among the Company, as borrower; the guarantors from time to time party thereto; BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders thereunder; and BioPharma Credit PLC, as collateral agent for the lenders (the “Credit Agreement”).”
BIOCRYST PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2022 results: revenue $79.5 million, net income $71.5 million, or $0.38 per share, EPS $0.38 per share. Guidance reaffirmed.
“molecules targeting C2, which are currently in lead optimization. Fourth Quarter 2022 Financial Results For the three months ended December 31, 2022, total revenues were $79.5 million, compared to $47.2 million in the fourth quarter of 2021 (+68 percent year-over-year). The increase was primarily due to $70.7 million in ORLADEYO net revenue in the fourth”
BIOCRYST PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2022 results: revenue $70.7 million. Guidance raised.
“for many years to come,” said Jon Stonehouse, president and chief executive officer of BioCryst. Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2022 was $70.7 million (+53 percent y-o-y). Preliminary, unaudited ORLADEYO net revenue for full year 2022 was $251.6 million (+105 percent y-o-y). Fourth Quarter and Full Year 2022 ORLADEYO Revenue”
BIOCRYST PHARMACEUTICALS INC reported third quarter ended September 30, 2022 results: revenue $75.8 million, net income $42.5 million, EPS $0.23 per share.
“For the three months ended September 30, 2022, total revenues were $75.8 million, compared to $41.0 million in the third quarter of 2021 (+85 percent year-over-year (y-o-y)). The increase was primarily due to $66.0 million in ORLADEYO net revenue in the third quarter of 2022. Research and development expenses for the third quarter of 2022 increased to $52.7 million from $50.0 million in the third quarter of 2021 (+6 percent y-o-y), primarily due to additional investment in the HAE program and expenses for BCX9250 prior to its discontinuation, partially offset by reduced costs related to the BCX9930 studies. Selling, general and administrative expenses for the third quarter of 2022 increased to $36.9 million, compared to $35.0 million in the third quarter of 2021 (+6 percent y-o-y). The increase was primarily due to increased investment to support the commercial launch of ORLADEYO. Interest expense was $24.8 million in the third quarter of 2022, compared to $14.1 million in the third qu”
Ryan Arnold was appointed as Chief Medical Officer at BIOCRYST PHARMACEUTICALS INC.
“Also effective September 15, 2022, Dr. Ryan Arnold will serve as the Company’s new Chief Medical Officer.”
William P. Sheridan changed role as Chief Development Officer at BIOCRYST PHARMACEUTICALS INC.
“Effective September 15, 2022, William P. Sheridan, MBBS, will serve as Chief Development Officer of the Company.”
Machelle Sanders was elected as Director at BIOCRYST PHARMACEUTICALS INC.
“On February 4, 2022, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) voted to increase the size of the Board from 11 directors to 12 directors and elected Machelle Sanders to fill the vacancy created by the enlargement of the Board, effective February 8, 2022 (the “Effective Date”).”
Amy McKee was elected as Director at BIOCRYST PHARMACEUTICALS INC.
“elected Amy McKee, M.D. to fill the vacancy created by the enlargement of the Board, effective September 20, 2021”
Steven Galson was appointed as Director at BIOCRYST PHARMACEUTICALS INC.
“elected Steven Galson, M.D. to fill the vacancy created by the enlargement of the Board, effective September 1, 2021”
Megan Sniecinski departed as Chief Business Officer at BIOCRYST PHARMACEUTICALS INC.
“Megan Sniecinski, Chief Business Officer of the Company, would separate from employment with the Company.”
Megan Sniecinski departed as Chief Business Officer at BIOCRYST PHARMACEUTICALS INC.
“On July 28, 2021, it was determined that Megan Sniecinski, Chief Business Officer of BioCryst Pharmaceuticals, Inc. (the “Company”), would separate from employment with the Company.”
Vincent J. Milano was elected as Director at BIOCRYST PHARMACEUTICALS INC.
“elected Vincent J. Milano to fill the vacancy created by the enlargement of the Board, effective July 26, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.